According to GlycoMimetics 's latest financial reports the company's current revenue (TTM) is $0.01 M. In 2022 the company made a revenue of $0.07 M a decrease over the years 2021 revenue that were of $1.15 M.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2023 (TTM) | $0.01 M | -86.67% |
2022 | $0.07 M | -93.53% |
2021 | $1.15 M | -88.59% |
2020 | $10.16 M | |
2019 | N/A | |
2018 | N/A | |
2017 | N/A | -100% |
2016 | $0.01 M | -99.91% |
2015 | $20.07 M | 33.56% |
2014 | $15.02 M | 276.37% |
2013 | $3.99 M |
Company | Revenue | Revenue differencediff. | Country |
---|---|---|---|
Johnson & Johnson JNJ | $93.02 B | 930,219,900.00% | ๐บ๐ธ USA |
Pfizer PFE | $58.49 B | 584,969,900.00% | ๐บ๐ธ USA |
Sanofi SNY | $50.35 B | 503,599,029.18% | ๐ซ๐ท France |
Palatin Technologies PTN | $7.09 M | 70,876.98% | ๐บ๐ธ USA |
bluebird bio
BLUE | $21.72 M | 217,160.00% | ๐บ๐ธ USA |